CSPC has a very strong financial position. As of 2022, its total debt outstanding is only 1.8% of its total cash in hand. Its annual capital expenditure for 2022 was CNY 1.8 billion. Given its CNY ...

CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement. CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, reported its unaudited financial results for ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

Chinese drug maker CSPC Pharmaceutical Group said on Thursday it signed a strategic partnership with Pfizer to launch a local brand of an oral COVID-19 treatment, in an attempt to improve the ...

CSPC Pharmaceutical Group (CHJTF) Company Description: CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products.

For the six months ended June 30, CSPC Pharmaceuticals had reported a nearly 50% drop in its net profit attributable to 137 million yuan ($19.39 million). ($1 = 7.7931 Hong Kong dollars) ...

CSPC Pharmaceutical Group has reported its unaudited consolidated financial results for the first nine months ending September 30, 2024. The company experienced a decline in total revenue and ...

CSPC Pharma gets an upfront fee of up to $150 million, development payments of up to $135 million and further fees of up to $1.55 billion if it hits sales milestones, as well as royalties.

AstraZeneca aims to hit that key protein target with an oral small molecule licensed from CSPC Pharmaceutical Group. By Frank Vinluan ...

CSPC Pharmaceutical Group Limited has recently executed an on-market share purchase for its share award scheme, acquiring 5,590,000 shares at an average price of HK$6.779 per share, amounting to a ...